51KA Stock Overview
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
AVITA Medical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.55 |
| 52 Week High | US$18.70 |
| 52 Week Low | US$7.55 |
| Beta | 1.29 |
| 1 Month Change | -50.00% |
| 3 Month Change | -50.00% |
| 1 Year Change | -46.07% |
| 3 Year Change | -55.33% |
| 5 Year Change | n/a |
| Change since IPO | -65.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 51KA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -7.4% | 0.7% | 2.0% |
| 1Y | -46.1% | -24.4% | 2.0% |
Return vs Industry: 51KA underperformed the German Biotechs industry which returned -24.4% over the past year.
Return vs Market: 51KA underperformed the German Market which returned 2% over the past year.
Price Volatility
| 51KA volatility | |
|---|---|
| 51KA Average Weekly Movement | 10.7% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 51KA's share price has been volatile over the past 3 months.
Volatility Over Time: 51KA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 207 | Jim Corbett | www.avitamedical.com |
AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company’s lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time.
AVITA Medical, Inc. Fundamentals Summary
| 51KA fundamental statistics | |
|---|---|
| Market cap | €205.48m |
| Earnings (TTM) | -€33.07m |
| Revenue (TTM) | €46.87m |
4.4x
P/S Ratio-6.2x
P/E RatioIs 51KA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 51KA income statement (TTM) | |
|---|---|
| Revenue | US$50.14m |
| Cost of Revenue | US$7.78m |
| Gross Profit | US$42.36m |
| Other Expenses | US$77.74m |
| Earnings | -US$35.38m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 13, 2024
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 84.48% |
| Net Profit Margin | -70.56% |
| Debt/Equity Ratio | 81.2% |
How did 51KA perform over the long term?
See historical performance and comparison